Key Findings:  Both (+)-enantiomers of cannabidiol (CBD) in this mouse model show potential therapeutic use in metabolic and immune-related disorders such as Type-1 diabetes and diabetic kidney disease by targeting type 1 and type 2 CB receptors.
Type of Study:  Animal Study
Study Result:  Positive
Study Location(s):  Germany, Spain
Year of Pub:  2021
Cannabinoids Studied:  Cannabidiol (CBD)
Phytocannabinoid Source:  Isolate
Chemotype:  Chemotype III
Receptors Studied:  CB1, CB2